Motif Bio plc (MTFB) IPO Opens Lower

Today's IPO for Motif Bio plc (NASDAQ: MTFB) opened for trading at $5.52 after pricing its initial public offering of approximately 2.44 million American Depositary Shares (ADSs) with 50% warrant coverage. Each ADS, representing 20 ordinary shares of Motif, and warrant to purchase 0.5 ADSs are being offered at an offering price to the public of $6.98 per ADS and warrant combination.

H.C. Wainwright & Co. is acting as the sole book-running manager for the U.S. offering.

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (REVIVE-1 and REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.

You May Also Be Interested In

• Bowhead Specialty Holdings (BOW) Files for Proposed IPO
• DiamondRock Hospitality (DRH) announces Jeffrey Donnelly has been appointed CEO, reaffirms guidance
• Serve Robotics Sees IPO of 8.89m Shares at $4.50 a Share